These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 1295414)
41. A possible role for propranolol in the treatment of renal osteodystrophy. Caro JF; Besarab A; Burke JF; Glennon JA Lancet; 1978 Aug; 2(8087):451-4. PubMed ID: 79809 [TBL] [Abstract][Full Text] [Related]
42. Serum markers of bone turnover in dialyzed patients grouped by level of intact parathyroid hormone. Grzegorzewska AE; Mlot-Michalska M Adv Perit Dial; 2006; 22():203-6. PubMed ID: 16983970 [TBL] [Abstract][Full Text] [Related]
43. Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study. Haarhaus M; Monier-Faugere MC; Magnusson P; Malluche HH Am J Kidney Dis; 2015 Jul; 66(1):99-105. PubMed ID: 25843703 [TBL] [Abstract][Full Text] [Related]
44. Hyperparathyroid bone disease in diabetic renal failure. Cundy TF; Humphreys S; Watkins PJ; Parsons V Diabetes Res; 1990 Aug; 14(4):191-6. PubMed ID: 2132193 [TBL] [Abstract][Full Text] [Related]
45. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group. Weinreich T; Ritz E; Passlick-Deetjen J Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540 [TBL] [Abstract][Full Text] [Related]
47. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484 [No Abstract] [Full Text] [Related]
48. Pattern of renal osteodystrophy in haemodialysis patients in Saudi Arabia. Huraib S; Souqqiyeh MZ; Aswad S; al-Swailem AR Nephrol Dial Transplant; 1993; 8(7):603-8. PubMed ID: 8396743 [TBL] [Abstract][Full Text] [Related]
49. Renal osteodystrophy: alpha-Heremans Schmid glycoprotein/fetuin-A, matrix GLA protein serum levels, and bone histomorphometry. Coen G; Ballanti P; Balducci A; Grandi F; Manni M; Mantella D; Pierantozzi A; Ruggeri M; Sardella D; Sorbo G; Bonucci E Am J Kidney Dis; 2006 Jul; 48(1):106-13. PubMed ID: 16797392 [TBL] [Abstract][Full Text] [Related]
50. Bone turnover markers predict type of bone histomorphometry and bone mineral density in Asian chronic haemodialysis patients. Laowalert S; Khotavivattana T; Wattanachanya L; Luangjarmekorn P; Udomkarnjananun S; Katavetin P; Eiam-Ong S; Praditpornsilpa K; Susantitaphong P Nephrology (Carlton); 2020 Feb; 25(2):163-171. PubMed ID: 30980579 [TBL] [Abstract][Full Text] [Related]
51. [Loss of bone substance in long-term dialysis--the value of serochemical parameters]. Schober HC; Abendroth K; Osten B; Kunkel S Z Urol Nephrol; 1989 Oct; 82(10):515-9. PubMed ID: 2609801 [TBL] [Abstract][Full Text] [Related]
52. Comparison of biochemical with radiological findings in renal osteodystrophy. Moorhead JF; Varghese Z; Tatler GL; Baillod RA; Wills MR Ann Clin Biochem; 1975 May; 12(3):126-31. PubMed ID: 15637920 [TBL] [Abstract][Full Text] [Related]
53. Evidence for a relationship between plasma immunoreactive calcitonin and bone disease in chronic renal failure. Kanis JA; Heynen G; Earnshaw M; Russell RG; Woods CG; Franchimont P; Gaspar S; Oliver D; Ledingham JG Adv Exp Med Biol; 1977; 81():571-9. PubMed ID: 899941 [No Abstract] [Full Text] [Related]